menu
    • menu

    Company profile for Renalys Pharma

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Renalys Pharma is a privately held, late-stage clinical biopharmaceutical company based in Japan, dedicated to advancing innovative therapeutics to address unmet needs in the management of renal disease, with a particular focus on Japanese and Asian patients. The mission of Renalys Pharma, Inc. is centered around enhancing the lives of patients in Japan and Asia through the development of groundbreaking therapeutics that contr...
    Renalys Pharma is a privately held, late-stage clinical biopharmaceutical company based in Japan, dedicated to advancing innovative therapeutics to address unmet needs in the management of renal disease, with a particular focus on Japanese and Asian patients. The mission of Renalys Pharma, Inc. is centered around enhancing the lives of patients in Japan and Asia through the development of groundbreaking therapeutics that contribute to the improved management of renal diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Renalys Pharmajapan Flag
    Country
    Country
    Japan
    Address
    Address
    Chuo-ku Tokyo, 103-0023
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://renalys.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Renalys Pharma Reports Positive Phase 3 Sparsentan Results
    Renalys Pharma Reports Positive Phase 3 Sparsentan Results

    26 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renalys-pharma-announces-positive-topline-results-from-phase-iii-study-of-sparsentan-in-japanese-patients-with-iga-nephropathy-302626218.html

    PR NEWSWIRE
    26 Nov 2025
    Share Share
    Renalys Pharma To Be Acquired By Chugai Pharmaceutical
    Renalys Pharma To Be Acquired By Chugai Pharmaceutical

    24 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renalys-pharma-to-be-acquired-by-chugai-pharmaceutical-302593653.html

    PR NEWSWIRE
    24 Oct 2025
    Share Share
    Renalys Pharma Backs Alport Syndrome Registry Study
    Renalys Pharma Backs Alport Syndrome Registry Study

    22 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renalys-pharma-announces-support-for-alport-syndrome-registry-study-organized-by-japanese-society-for-pediatric-nephrology-302590847.html

    PR NEWSWIRE
    22 Oct 2025
    Share Share
    Renalys Pharma Secure Japan PMDA Deal For Sparsentan Ph3 for FSGS
    Renalys Pharma Secure Japan PMDA Deal For Sparsentan Ph3 for FSGS

    17 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renalys-pharma-reaches-japan-pmda-agreement-on-phase-iii-clinical-trials-of-sparsentan-for-focal-segmental-glomerulosclerosis-fsgs-and-alport-syndrome-as-302587260.html

    PR NEWSWIRE
    17 Oct 2025
    Share Share
    Renalys Completes Phase III Trial Data Collection For Sparsentan
    Renalys Completes Phase III Trial Data Collection For Sparsentan

    10 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renalys-announces-completion-of-primary-endpoint-data-collection-for-phase-iii-clinical-trial-of-sparsentan-for-iga-nephropathy-in-japan-302580549.html

    PR NEWSWIRE
    10 Oct 2025
    Share Share
    Renalys Completes Phase 3 Enrollment For Sparsentan In Japan
    Renalys Completes Phase 3 Enrollment For Sparsentan In Japan

    30 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/renalys-pharma-announces-completion-of-patient-enrollment-in-registrational-phase-iii-clinical-trial-of-sparsentan-for-iga-nephropathy-in-japan-302364036.html

    PR NEWSWIRE
    30 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search